BamSEC and AlphaSense Join Forces
Learn More

Amylyx Pharmaceuticals Inc. – Material Contracts

NASDAQ: AMLX    
Share price (3/24/26): $13.66    
Market cap (3/24/26): $1.510 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-K 3 pages Amylyx Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 4 pages Performance-Based Restricted Stock Unit Award Agreement for Company Employees Under the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan Incremental Number of Restricted Stock Units Vested Performance Condition
12/34/56
EX-10.11
from 10-K 29 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 56 pages Asset Purchase Agreement by and Between Amylyx Pharmaceuticals, Inc., or a Wholly Owned Subsidiary Thereof, as Purchaser, and Eiger Biopharmaceuticals, Inc., as Seller Dated as of June 21, 2024
12/34/56
EX-10.1
from 10-Q 4 pages Amylyx Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.17
from 10-K 10 pages Separation and Release Agreement
12/34/56
EX-10.15
from 10-K 29 pages Employment Agreement
12/34/56
EX-10.13
from 10-K 3 pages 2nd Amendment to Employment Agreement
12/34/56
EX-10.1
from 10-Q 26 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”
12/34/56
EX-10.4
from 10-Q 4 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”
12/34/56
EX-10.3
from 10-Q 2 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Amendmement No. 2 to the Product Agreement Between Patheoninc. and Amylyxpharmaceuticals, Inc
12/34/56
EX-10.2
from 10-Q 3 pages Amendment No. 1, Rev 1 to the Productagreement Between Patheon Inc. and Amylyxpharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 3 pages Amylyx Pharmaceuticals, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10
from 10-K 29 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 2 pages Amendment to Employment Agreement
12/34/56
EX-10.16
from S-1/A 14 pages Employment Agreement
12/34/56
EX-10.15
from S-1/A 14 pages Employment Agreement
12/34/56
EX-10.14
from S-1/A 14 pages Employment Agreement
12/34/56
EX-10.13
from S-1/A 15 pages Employment Agreement
12/34/56
EX-10.12
from S-1/A 15 pages Employment Agreement
12/34/56